在住院COVID-19患者中对AT缺乏症的新描述
B M Parker1, K G Proctor, R Guerra
1DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. bmp55@med.miami.edu.
European review for medical and pharmacological sciences
|February 6, 2025
概括
在COVID-19患者中,往往存在抗血素 (AT) 缺乏. 在这些患者中,AT3补充对凝血病,停留时间或死亡率没有显著影响,没有观察到任何不良事件.
科学领域:
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
- 临界护理医学 临界护理医学
背景情况:
- 抗血素 (AT) 具有抗炎和抗凝固特性.
- 在COVID-19中AT的作用和AT缺乏症的患病率仍然不清楚.
- 假设:AT3缺乏在COVID-19中很常见,AT3补充可能会减轻COVID-19凝血病.
研究的目的:
- 为了调查COVID-19患者抗血缺乏症的患病率.
- 评估抗血素III (AT3) 补充剂在治疗COVID-19凝血病的有效性.
- 在这个患者群体中评估外源AT3的安全性.
主要方法:
- 预期随机对照试验涉及50名受试者.
- 血AT3<100%的患者被随机分配到标准护理 (SOC) 或SOC + AT3.3中.
- 一个具有AT3>100%的参考组获得了SOC.
主要成果:
- 很大一部分COVID-19患者 (76%) 的AT3水平低于100%,22%的AT3水平低于80%.
- 两组之间传播性血管内凝血 (DIC) 评分的变化没有显著差异 (p=0.63).
- 住院时间 (p=0.176) 和死亡率 (p=0.56) 在治疗组之间没有显著差异.
结论:
- 在很大一部分患者中,COVID-19与相对AT3缺乏症有关.
- 外源AT3的使用是安全的,没有观察到出血并发症或与药物相关的不良事件.
- 需要进一步的研究来探索更高的AT3剂量和更高风险的患者群体.
相关概念视频
01:29Acute Respiratory Failure-V
121
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
121
01:21Acute Respiratory Failure-II
164
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
164
01:28Pneumonia IV: Management
296
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
296
01:23Acute Respiratory Failure-IV
120
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
120
01:30Acute Respiratory Failure-III
153
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
153
01:29Pulmonary Tuberculosis I
220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220